← Scroll for more →
ELI LILLY & Co (LLY)
Pharmaceutical Preparations
Latest Price
$1157.08
TTM P/E
38.83
Normalized P/E
83.99
Div Yield
0.58%
Book Value
35.97
P/B Ratio
32.16
Valuation metrics
adjust assumptions →EPS: $22.95
Book value / share: $29.51
Formula: √(22.5 × EPS × BVPS)
Graham Number
$123.44
89% downside
Norm. op. income: $7.1B (median of 7yr)
Tax rate: 14%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$28.99
97% downside
Base FCF: $5.2B (median of recent 5yr)
Growth: 21%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$278.09
76% downside
EPS: $22.95
Target P/E: 84×
Formula: EPS × P/E
P/E Fair Value
$1,927.80
+67% upside
Institutional Ownership
89.9% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Lilly Endowment Inc | 90.38M | $108.40B | 10.11% | -1.52M | 2026-06-30 |
| BlackRock, Inc. | 67.54M | $81.01B | 7.56% | +1.05M | 2026-06-30 |
| Vanguard Capital Management LLC | 53.53M | $64.20B | 5.99% | +167.1K | 2026-06-30 |
| PNC Financial Services Group, Inc. | 51.32M | $61.56B | 5.74% | -6.2K | 2026-06-30 |
| State Street Corp | 36.22M | $43.44B | 4.05% | +605.8K | 2026-06-30 |
| FMR LLC | 28.46M | $34.14B | 3.19% | +2.12M | 2026-06-30 |
| Capital Research Global Investors | 20.87M | $25.04B | 2.34% | -3.76M | 2026-06-30 |
| Vanguard Portfolio Management LLC | 20.86M | $25.02B | 2.33% | -117.8K | 2026-06-30 |
| Geode Capital Management, LLC | 20.31M | $24.27B | 2.27% | +119.0K | 2026-06-30 |
| Morgan Stanley | 16.23M | $19.46B | 1.82% | +788.9K | 2026-06-30 |